Ligand Pharmaceuticals Incorporated (LGND)
Fixed asset turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 167,133 | 131,314 | 196,245 | 277,133 | 186,419 |
| Property, plant and equipment | US$ in thousands | — | — | 27,491 | 32,749 | 14,434 |
| Fixed asset turnover | — | — | 7.14 | 8.46 | 12.92 |
December 31, 2024 calculation
Fixed asset turnover = Revenue ÷ Property, plant and equipment
= $167,133K ÷ $—K
= —
The fixed asset turnover ratio for Ligand Pharmaceuticals Incorporated has shown a declining trend over the past few years. In 2020, the company achieved a solid fixed asset turnover of 12.92, indicating that it generated $12.92 in revenue for each dollar invested in fixed assets. However, this ratio decreased to 8.46 in 2021 and further dropped to 7.14 in 2022. This declining trend suggests that the company may be becoming less efficient in generating revenue from its fixed assets.
The absence of data for 2023 and 2024 makes it challenging to assess the current performance accurately. It is essential for the company to closely monitor its fixed asset turnover ratio moving forward to ensure optimal utilization of its fixed assets and maximize revenue generation. Suggestions for improvement could include evaluating the efficiency of asset utilization, exploring opportunities for asset optimization, and implementing strategies to increase revenue relative to fixed asset investments.
Peer comparison
Dec 31, 2024